학술논문
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
Document Type
Article
Author
Goodall, Ruth L; Meredith, Sarah K; Nunn, Andrew J; Bayissa, Adamu; Bhatnagar, Anuj K; Bronson, Gay; Chiang, Chen-Yuan; Conradie, Francesca; Gurumurthy, Meera; Kirenga, Bruce; Kiria, Nana; Meressa, Daniel; Moodliar, Ronelle; Narendran, Gopalan; Ngubane, Nosipho; Rassool, Mohammed; Sanders, Karen; Solanki, Rajesh; Squire, S Bertel; Torrea, Gabriela; Tsogt, Bazarragchaa; Tudor, Elena; Van Deun, Armand; Rusen, I D; Adilaa, Oyunchimeg; Alexandru, Sofia; Bellenger, Katharine; Bennet, Jaclyn; Bennet, Deborah; Bindroo, Priyanka; Borisagar, Ghanshyam; Cook, Claire; Dalai, Doljinsuren; Davis, Andrew; de Jong, Bouke; Dodds, Wendy; Duckworth, Lynette; Gahima, Nonhlanhla; Gebreegziabher, Belay; Goldfeld, Anne; Hanifa, Mahmud; Hughes, Gareth; Kimuli, Ivan; Komrska, Jan; Lomtadze, Nino; Murphy, Brendan; Mwelase, Thando; Nalunjogi, Joanitah; Patel, Leena; Pirlog, Irina; Qawiy, Ishmael; Rauchenberger, Mary; Rigouts, Leen; Roach, Carol; Rosu, Laura; Santos-Filho, Ezio; Senguttuvan, Thirumaran; Sisay, Million; Sridhar, Rathinam; Srinivasulu, Vignes; Teferi, Mekonnen; Teklu, Helen; Tsegeen, Narangarav; van Amsterdam, Odette; White, Lisa; Whitney, Johanna; Zagd, Chuluunbaatar
Source
The Lancet; November-December 2022, Vol. 400 Issue: 10366 p1858-1868, 11p
Subject
Language
ISSN
01406736; 1474547X
Abstract
The STREAM stage 1 trial showed that a 9-month regimen for the treatment of rifampicin-resistant tuberculosis was non-inferior to the 20-month 2011 WHO-recommended regimen. In STREAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM stage 1 regimen.